TRPV4 and glioblastoma: To test this hypothesis, we first investigated the migration of glioblastoma cells after treatment with the TRPV4 agonist GSK1016790A (GSK1, 10 nM) or the antagonist GSK2193874 (GSK2, 100 nM).